AV THERAPEUTICS Investor presentation JAN 2014 Except for historical information, the statements made in this presentation are forward looking statements involving significant risks and uncertainties. “Better Treatment of Cancer through Innovation” A New York Based Biotechnology Company 1
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
AV THERAPEUTICS
Investor presentation
JAN 2014
Except for historical information, the statements made in this presentation are forward looking statements involving significant risks and uncertainties.
Forward-Looking DisclosureAll statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for AV Therapeutic(The Company)
products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to
be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s registration statement on Form S-1 and
other reports filed with the Securities and Exchange Commission which is available for review at www.sec.gov.
Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's
business. The Company disclaims any intent or obligation to update these forward-looking statements.
• Developing cancer therapeutics & immunotherapeutic vaccines that can be used alone or in combination with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence.
• Based on the ability of certain proprietary reagents to re-educate or reprogram an immune system to target previously unidentified micro-metastases.
• Clinically developing both approaches for metastatic and early-stage prostate cancer.
Abraham Mittelman , M.D., Chief Executive Officer and Chairman of the Board• Oncologist and professor
at New York Medical College (NYMC) with over 30 years of experience in patient treatment and clinical trials. Over 200 peer reviewed publications and presentations, trained at Memorial Sloan Kettering Cancer Center (Memorial).
Raj Tiwari, Ph.D., Chief Scientific Officer• Professor of
Microbiology & Immunology and Graduate Program Director at NYMC. Over 30 years of research experience with over 150 peer reviewed publications and presentations. Trained at Memorial, inventor of several patents involving Capridine and Peptide based Cancer Vaccine Technology.
Morton Coleman, M.D., Vice President, Director of Clinical Development • Clinical Professor at Weill
Medical College of Cornell University and Director of the Center for Lymphoma and Myeloma at New York Presbyterian Hospital – Weill Cornell. Chairman, Medical Affiliate Board of Lymphoma Research Foundation, over 400 publications and designated one of the “Best Doctors in America”
Robert Pollock, President• Over 40 years
business experience. Founder and managing partner of Continuum Partners, a global network security and business development consulting firm.
Jan Geliebter, Ph.D., Secretary, VP Genomic Platforms• Professor of
Microbiology & Immunology at NYMC with over 30 years of cancer research experience and over 100 peer reviewed publications. Holder of multiple patents, including a BCG-based prostate cancer vaccine
Debabrata Banerjee, Ph.D., VP Preclinical Development• Associate Professor
of Medicine and Pharmacology, The Cancer Institute of New Jersey. Over 25 years of experience in preclinical and experimental therapeutics with over 125 publications and presentations. Inventor of several patents.
• Joseph Bertino, MD, Associate Director and Chief Scientific Officer, The Cancer Institute of New Jersey and past President of the American Association for Cancer Research and The American Association of Clinical Oncologists, organizations of over 50,000 researchers, worldwide. He is the founding Editor of the Journal of Clinical Oncology.
• Charles Cantor, PhD, is Director of the Center for Advanced Biotechnology at Boston University and Chief Scientific Officer at Sequenom, Inc. in La Jolla (a publicly traded company). He has published more than 400 articles, and has been awarded more than sixty (60) patents. He is most known for his authoring of the book, Genomics: The Science and Technology Behind the Human Genome Project.
• Roy G. Smith, PhD, is the Director of then Huffington Center on Aging, Professor in the Department of Molecular and Cellular Biology, and Professor in the Department of Medicine at Baylor College of Medicine. He was previously Vice President of Basic Research at Merck and was responsible for identifying new drug targets for metabolic diseases
• Pramod Srivastava, PhD, is a Professor of immunology at the University of Connecticut, where he holds an Endowed Chair in Cancer Immunology and is the Director of the Cancer Center and the Scientific Founder of Antigenics. He is among the founding members of the Academy of Cancer Immunology.